We are a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines. We are committed to improving patients’ lives worldwide by targeting diseases with high unmet needs. Our R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Our portfolio comprises discovery through to Phase 4 programs in immunology, oncology, and other indications. Our first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan.
View Top Employees from Galapagos| Website | http://www.glpg.com |
| Ticker | GLPG |
| Revenue | $22.9 billion |
| Funding | $295.5 million |
| Employees | 1,372 (1,372 on RocketReach) |
| Founded | 1999 |
| Address | l11 a3 Generaal De Wittelaan, Mechelen, Flanders 2800, BE |
| Phone | (321) 534-2900 |
| Fax | (321) 534-2901 |
| Technologies |
JavaScript,
HTML,
PHP
+70 more
(view full list)
|
| Category | Biotechnology Research, Pharmaceuticals, Biopharma, Healthcare, Biotechnology, Health Care, Science and Engineering, Clinical Trials, Medical |
| Web Rank | 690412 |
| Web Visits | 54280 |
| Keywords | galapagos, filgotinib, galapagos pharma, galapagos nv, biotechnologie galapagos |
| SIC | 28, 873, 87, 283 |
| NAICS | 54171, 62151, 5417, 325, 621, 541, 6215, 541711, 62, 54, 32 |
Looking for a particular Galapagos employee's phone or email?
Galapagos Questions
The Galapagos annual revenue was $22.9 billion in 2023.
Paul Stoffels is the CEO of Galapagos.
1,372 people are employed at Galapagos.
Galapagos is based in Mechelen, Flanders.
The NAICS codes for Galapagos are [54171, 62151, 5417, 325, 621, 541, 6215, 541711, 62, 54, 32].
The SIC codes for Galapagos are [28, 873, 87, 283].
Top Galapagos Employees
-
35+
-
25+
-
1
-
15+
-
43
-
34
Related Companies
